Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221280 | 0.92 | CRHR1 (0.91) | CRHR1 | |
| SCHEMBL7221040 | 0.90 | CRHR1 (0.78) | CRHR1 | |
| SCHEMBL7215846 | 0.90 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL7217350 | 0.87 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL7216295 | 0.87 | CRHR1 (0.82) | CRHR1 | |
| SCHEMBL7216801 | 0.86 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL7471870 | 0.84 | CRHR1 (0.76) | CRHR1 | |
| SCHEMBL7222251 | 0.81 | CRHR1 (0.79) | CRHR1 | |
| SCHEMBL7222321 | 0.77 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL7217794 | 0.76 | CRHR1 (0.58) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548509-B2 | For diagnosis and therapy of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety | NEUROGEN CORPORATION | 2003-04-15 | — | — | US | claimed |
| EP-0960110-B8 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | YUAN JUN (US) | 2002-05-16 | — | — | US | claimed |
| EP-0960110-B1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-03-20 | — | — | EP | claimed |
| EP-0960110-A1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998029413-A1 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | claimed |
| US-6548509-B2 | For diagnosis and therapy of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety | NEUROGEN CORPORATION | 2003-04-15 | — | — | US | disclosed |
| EP-0960110-B8 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | YUAN JUN (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0960110-B1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6211187-B1 | POST-TRAUMATIC STRESS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0960110-A1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998029413-A1 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.